neuropathic pain
Pain · 2011–2022
No submission for this condition has carried consumer input, including the 3 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pregabalin Treatment of neuropathic pain in adults. The controlled release formulation is proposed under the same restrictions and clinical criteria as the PBS-listed… | May 2022 | Deferred | unclear |
| pregabalin Treatment of neuropathic pain in adults. The controlled release formulation is proposed as a once-daily alternative to the immediate release formulation. | Nov 2021 | Deferred | unclear |
| pregabalin Treatment of neuropathic pain in adults, and as adjunctive therapy in adults with partial seizures with or without secondary generalisation. | Nov 2021 | Deferred | none received |
| pregabalin Initiation and continuation of treatment for neuropathic pain in adults, including those with reduced doses due to renal impairment. | Mar 2012 | Recommended with restriction | no section in document |
| pregabalin Neuropathic pain in adults, including diabetic peripheral neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes. | Mar 2012 | Recommended with restriction | no section in document |
| pregabalin Initial and continuing treatment of neuropathic pain in patients who meet certain criteria. | Mar 2011 | Not recommended | no section in document |
What the PBS pays
$109M in government benefit over 2024–25, across 6,704,202 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| Pregabalin | $54.3M |
| pregabalin | $54.3M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| gabapentinALKEM GABAPEN gabapentin 100 mg capsule blister pack | 1999 | 87 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.